Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs BAY 1834845 (Primary) ; BAY 1834845 (Primary)
- Indications Pelvic inflammatory disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 16 Jul 2017 Planned End Date changed from 30 Oct 2017 to 28 Mar 2018.
- 16 Jul 2017 Planned primary completion date changed from 18 Sep 2017 to 28 Feb 2018.
- 19 May 2017 Planned End Date changed from 8 Sep 2017 to 30 Oct 2017.